Navigation Links
PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
Date:9/3/2009

nly FDA-approved indication for such products. However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About Bacillus - ACT 2009

Bacillus - ACT 2009 is the third joint conference representing a fusion of two conferences: the 8th International Conference on Anthrax and the 6th International Workshop on the Molecular Biology of Bacillus cereus, Bacillus anthracis and Bacillus thuringiensis, and is organized by the American Society for Microbiology (ASM). The major mission of the conference is to promote stimulating and fruitful interactions between investigators involved in research related to the physiology, genetics, molecular biology, and pathogenicity of these bacteria and to the prevention and treatment of diseases they cause. The conference includes scientific sessions consisting of oral or poster presentations selected from the abstract submissions.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim((R))-- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia((R)) -- a novel bioscavenger for the prevention and treatme
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes ... Reported sales were $697 million compared to $701 million ... by 8%, and changes in foreign currency exchange rates ... 1%. , By business unit, organic sales growth ... in SAFC Commercial. , Reported diluted EPS was ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... the University of Pennsylvania demonstrates a more consistent and ... has promising applications in a variety of fields, and ... Physics. As explained in a recently published study, ... graphene that is just a single atom thick over ...
... QUINCY, Mass., March 2, 2011 Myriant Technologies, ... of renewable bio-based chemicals, announces the addition of ... effective immediately.  Mr. Ferguson, 56, is the former ... global chemical company engaged in the manufacture and ...
... N.C., March 2, 2011 Cempra Pharmaceuticals Inc. today ... executive officer, will present at the Cowen and Company ... March 7, 2011, at The Boston Marriott Copley Place ... the company,s two leading antibiotic clinical programs, solithromycin for ...
Cached Biology Technology:Penn physicists develop scalable method for making graphene 2Penn physicists develop scalable method for making graphene 3Myriant Technologies, Inc. Announces J. Brian Ferguson to Join Advisory Board 2
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... The American Physiological Society (APS; www.the-APS.org ) announced ... Fellowships to TanYa Gwathmey and Kesia Mathis. This is ... Gwathmey, an African-American, is a postdoctoral fellow in the ... University School of Medicine in Winston-Salem, N.C. There she ...
... previously-unreported callus hairs growing in the flesh of mature ... storage implications for commercial growers. To find out ... Mary Parker of the Institute of Food Research. Apples ... history and Fuji apples are particularly prized for their ...
... the launch of Bioscience Horizons, a unique peer-reviewed journal ... in the UK and Republic of Ireland. ... a collaboration between the universities of Leeds, Nottingham, Reading, ... to provide a forum for the brightest undergraduates in ...
Cached Biology News:APS names 2 minority outreach fellows 2APS names 2 minority outreach fellows 3Popular apple variety harbors unusual cell growth 2
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
...
Biology Products: